Compare SWAG & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWAG | MIRA |
|---|---|---|
| Founded | 1994 | 2020 |
| Country | United States | United States |
| Employees | 156 | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.1M | 43.7M |
| IPO Year | N/A | 2023 |
| Metric | SWAG | MIRA |
|---|---|---|
| Price | $2.06 | $0.91 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 32.8K | ★ 66.9K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.37 | $0.90 |
| 52 Week High | $3.50 | $2.45 |
| Indicator | SWAG | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 45.98 | 43.62 |
| Support Level | $1.59 | $0.91 |
| Resistance Level | $2.04 | $1.01 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 14.74 | 21.16 |
Stran & Co Inc is an outsourced marketing solutions provider, working closely with customers to develop sophisticated marketing programs that leverage promotional products and loyalty incentive expertise. In addition to selling branded products, it offers its clients custom sourcing capabilities, which is a flexible and customizable e-commerce solution for promoting branded merchandise and other promotional products, managing promotional loyalty and incentives, print collateral, event assets, order and inventory management, and designing and hosting online retail pop-up shops. The company's segment consists of the Stran segment and the SLS segment. The company generates the majority of its revenue from the Stran segment.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.